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Background: Mutations affecting RAS genes are now established predictive markers of nonresponse to anti-EGFR antibodies in
advanced CRC. This analysis assessed the prognostic and predictive impact of extended RAS and PIK3CA gene mutation status in
patients receiving capecitabine plus or minus bevacizumab (±mitomycin C) in the randomised phase III MAX study.
Methods: DNA was extracted from archival macrodissected formalin-fixed paraffin-embedded tumour tissue. Mutation status was
determined using pyrosequencing, confirmed with Sanger sequencing (for equivocal RAS) and correlated with efficacy outcomes.
Predictive analyses were undertaken using a test for interaction involving both C vs CBþCBM.
Results: Of the available 280 of the 471 (59.4%) patients, mutations in KRAS exons 2, 3 and 4 and NRAS 2, 3 and 4 were as
follows: 32%, 2.9%, 2.2%, 1.4%, 0.7% and 0% (total RAS MT 39%). The PIK3CA MT rate was 7.5% exon 9 and 3.6% exon 20.
Extended RAS gene mutation status (WT vs MT) had no prognostic impact for PFS (HR 0.91 (0.71–1.17)) or OS (HR 0.95 (0.71–
1.25)). The RAS gene mutation status was not predictive of the effectiveness of bevacizumab for PFS (HR 0.56 (0.37–0.85) for
RAS MT and HR 0.69 (0.5–0.97) for RAS WT; P for interaction 0.50). The PIK3CA mutation was neither predictive for
bevacizumab effect nor prognostic.
Conclusion:Of KRAS exon 2 WT patients, 10% had additional RASmutations. Neither all RAS gene mutation status nor PIK3CA
mutation status was prognostic for PFS or OS, or predictive of bevacizumab outcome in patients with advanced CRC.
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The management of advanced colorectal cancer has improved
significantly over recent years. Targeted or biological agents
provide additional benefit to standard chemotherapy. The most
important targets for biological agents in metastatic colorectal
cancer (mCRC) are the epithelial growth factor receptor (EGFR)
and the vascular endothelial growth factor-A (VEGF-A). With
targeted agents there was hope that better patient selection would
follow and this has been the case for anti-EGFR therapy, but it
remains elusive for therapy targeting VEGF.
The KRAS gene exon 2 mutation is predictive of nonresponse to
EGFR-targeted monoclonal antibody (MAb) therapy across all
treatment lines, either as a single agent or in combination with
irinotecan- or oxaliplatin-based chemotherapy (Amado et al, 2008;
Karapetis et al, 2008; Bokemeyer et al, 2011; Van Cutsem et al,
2011). More recent evidence assessing the impact of additional RAS
mutations (KRAS exons 3 and 4 and NRAS exons 1–4) has further
defined the group of patients who do not respond to anti-EGFR
agent. Douillard et al (2013) and Peeters et al (2014) have reported
that additional RAS mutations occur in 17–18% of patients
previously classified as KRAS WT and that this group also do not
respond to anti-EGFR therapy. Importantly, the recently published
results from the PEAK trial reported extra RAS mutations in 23%
of KRAS exon 2 WT patients, highlighting the potential for
significant clinical impact (Schwartzberg et al, 2014). Determina-
tion of extended RAS status is therefore now recommended in
advanced CRC patients being considered for anti-EGFR-targeted
therapy and current evidence suggests that patients with a mutated
RAS should not receive such therapy.
Phosphatidylinositol 3-kinases (PI3K) are a family of three lipid
kinases. Class 1A molecules are heterodimers of regulatory (p85)
and catalytic (p110) subunits and in CRC the p110a isoform is
encoded by PIK3CA and is mutated in 15–18% of patients (De
Roock et al, 2011; Karapetis et al, 2014). More than 80% of these
mutations occur in exon 9 or 20, with exon 9 and exon 20 making
up 60–65% and 20–25%, respectively. PIK3CA mutations can co-
occur with RAS mutations. Mutations of PIK3CA are thought to be
potentially predictive of anti-EGFR effect, although prediction of
cetuximab activity is thought to be primarily associated with exon
20 mutations (Sartore-Bianchi et al, 2009; De Roock et al, 2010).
The low frequency of exon 20 mutations (3–5% in total) however
makes assessment of these results difficult to interpret and the
impact of PIK3CA mutations on prognosis is still uncertain (Day
et al, 2013; Karapetis et al, 2014). More importantly, the question
of whether PIK3CA may have some role in tumour angiogenesis
and therefore anti-VEGF therapy has been postulated. In this
setting, a difference based on type of mutation is also unclear (Jiang
and Liu, 2009).
Bevacizumab (anti-VEGF MAb) in combination with che-
motherapy (single agent or combination) is an accepted standard
of care for advanced colorectal cancer (Hurwitz et al, 2005; Saltz
et al, 2008; Tebbutt et al, 2010). Unlike EGFR MAbs, there remains
no reliable and reproducible predictive marker to assist in patient
selection. In solid tumours, VEGF and EGFR pathways have been
shown to interact effecting an increase in angiogenesis (Ellis, 2004;
Ciardiello et al, 2006), although we have previously reported results
from the MAX trial that failed to indicate any relationship between
outcomes of anti-VEGF therapy and KRAS exon 2 and BRAF
mutation status (Price et al, 2011). These results confirmed a
previous but smaller retrospective analysis (Ince et al, 2005). Both
of these analyses were based on KRAS exon 2 mutation status
alone. With additional RAS mutation rates as high as 23%, there
has been renewed interest in the potential interaction between the
EGFR and VEGF pathway.
This analysis was performed to explore the rate of additional
RAS mutations in a first-line population randomised within a trial
focussing on anti-VEGF therapy and to further assess whether a
change to an extended RAS mutation population has any impact
on the predictive and prognostic outcomes of extended RAS MT vs
WT. In addition, we undertook an analysis of PIK3CA mutation
status (exons 9 and 20 combined), exploring any interaction with
progression-free survival (PFS), overall survival (OS) and response
rate (RR) in patients receiving anti-VEGF therapy with bevacizu-
mab when combined with capecitabine in the randomised phase III
MAX study.
MATERIALS AND METHODS
Patients and study design. The MAX study design and eligibility
criteria have been reported previously (Tebbutt et al, 2010). The
primary objective of this phase III study was to evaluate the effect
of adding bevacizumab with or without mitomycin to capecitabine
on PFS among patients receiving first-line chemotherapy for their
mCRC. Enrollment of patients in the original trial occurred
between July 2005 and June 2007. Patients were randomly assigned
to receive capecitabine (C); capecitabine and bevacizumab (CB);
and capecitabine, bevacizumab and mitomycin C (CBM). All
patients who participated in the MAX translational studies
provided written informed consent at the time of study enrolment.
Ethics approval for translational studies was obtained centrally.
Tumour collection and processing. Tissue consent and collection
was performed at the time of trial commencement before this
planned biomarker analysis. Formalin-fixed, paraffin-embedded
samples of tumour tissue from archival specimens collected at the
time of cancer diagnosis were retrieved from storage at hospital
pathology departments. A histopathologist reviewed cases and if
deemed to have o50% malignant crypts in the section, the tissue
was macrodissected to ensure a high proportion (90%) of tumour
cells. Assays of tissue samples for KRAS (exons 2, 3 and 4), NRAS
(exons 2, 3 and 4) and PIK3CA (exons 9 and 20) mutations were
performed by investigators who were blinded to patient outcomes.
Patients were classified as mutated (MT) if a mutation was detected
in any of the exons examined, or wild-type (WT) in the absence of
any mutation, for RAS and PIK3CA, respectively.
Mutation analyses. Mutation analysis of RAS and PIK3CA genes
was performed using genomic DNA extracted from formalin-fixed,
paraffin-embedded tissue sections (QIAamp DNA FFPE Tissue
Kit, Qiagen, Carlsbad, CA, USA) and pyrosequencing performed
by the Perth node of the Australian Genome Research Facility
(AGRF) using the PyroMark Q24 Pyrosequencing system (Qia-
gen). The sensitivity for this platform is 2% mutant to WT alleles; a
cutoff of 10% was used to call mutations based on prior
recommendations for pyrosequencing. Full details are described
in Supplementary File online. Variant sequences were confirmed
by Sanger sequencing using both forward and reverse primers
(AGRF).
Statistical analysis. All randomly assigned patients for whom data
on KRAS, NRAS and PI3K mutation status were available were
included in this analysis. PFS, the primary end point, was defined
as the time from randomisation until documented evidence of
disease progression according to the Response Evaluation Criteria
in Solid Tumours (RECIST) version 1.0, the occurrence of new
disease or death from any cause. The secondary end points were
OS, defined as the time from randomisation until death from any
cause, and RR, defined according to RECIST version 1.0.
The PFS and OS of patients in each RAS group (MT vsWT) and
treatment groups (C vs CB and CBM) were summarised using
Kaplan–Meier curves, and the difference between these groups was
compared using log-rank test, with the hazard ratio (HR) and its
95% confidence interval (CI) calculated from a Cox regression
model with a single covariate. A Cox regression model with
treatment covariate (C vs CB and CBM), RAS status and their
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interaction was used to assess whether RAS was predictive of
bevacizumab treatment efficacy. If no significant treatment
interaction was detected, multivariate proportional hazards
regression model was fitted to data for all patients, with RAS
status and other protocol prespecified baseline covariates in the
model to assess whether RAS was an independent prognostic
factor.
We calculated the odds ratio (OR) and its 95% CI using
univariate and multivariate logistic regression models to compute
the difference in RR for the RAS group. A logistic regression model
with treatment covariate, RAS status and their interaction was used
to assess whether RAS was predictive of an effect of bevacizumab
on RR.
The same methodologies were adopted in assessing the
predictive and prognostic values of PIK3CA.
We also compared baseline characteristics of patients with and
without tumour samples available for mutational analysis. Multi-
variate logistic regression model was also performed to identify
predictors (if any) of tumour samples available for mutational
analysis.
All reported P-values were two sided and were not adjusted for
multiple testing.
RESULTS
Characteristics of the patients. Of the 471 patients who under-
went randomisation, a total of 280 tumour specimens (n¼ 95 from
the C group, n¼ 99 from the CB group and n¼ 86 from the CBM
group) were available and examined for RAS, accounting for 59.4%
of the total study population (Figure 1). The median follow-up
time of these patients was 30.2 months (range 0.4 to 42.4). Tumour
specimens from the remaining patients could not be retrieved, were
not suitable for mutational analysis or had insufficient DNA for
mutational analysis to be performed for both KRAS and NRAS.
The characteristics of patients with and without tissue sample
available for mutational analysis were similar aside from a higher
rate of primary resection and lower rate of residual local disease in
the tissue available group (Supplementary Table 1 online),
reflecting the amount of tissue available that will be greater in a
resected primary specimen when compared with a colonoscopic or
metastasis biopsy. In multivariate logistic regression of baseline
characteristics, prior resection of primary tumour (OR 6.98,
Po0.001) and no prior radiotherapy (OR 0.47, Po0.01) were
associated with having tumour specimens available for mutational
analysis.
A total of 276 tumour specimens (n¼ 89 from the C group,
n¼ 97 from the CB group and n¼ 90 from the CBM group) were
examined for PIK3CA mutation status, accounting for 58.6% of the
total study population. The baseline characteristics were balanced
between treatment groups in the tissue subpopulation
(Supplementary Table 1).
The RAS mutation was detected in 108 (38.9%) patients.
Mutation was detected in KRAS exon 2 (n¼ 89), KRAS exon 3
(n¼ 8), KRAS exon 4 (n¼ 5), NRAS exon 2 (n¼ 4), NRAS exon 3
(n¼ 2) but none for NRAS exon 4. One patient had mutation in
both KRAS exons 2 and 4. A total of 19 patients who were KRAS
exon 2 WT had other RASmutations (10%). PIK3CAmutation was
rare and detected in only 30 patients (10.8%; exon 9, n¼ 20; exon
20, n¼ 9; exons 9 and 20, n¼ 1).
Among the 262 patients with tumour specimens tested and
results available for KRAS, NRAS and PIK3CA mutation status, 13
(5.0%) patients had both RAS and PIK3CA mutations, 16 (6.1%)
RAS WT patients had PIK3CA mutation and 80 (30.5%) PIK3CA
WT patients had RAS mutation.
Baseline characteristics by mutation status are summarised in
Table 1. Clinical outcomes were comparable with no significant
difference in primary or secondary clinical outcomes between the
total study population and the patients who were evaluated for RAS
mutations (Tables 2 and 3).
Progression-free survival. Among patients with RAS MT tumour,
the median PFS was 6.2 months in the group receiving C and 8.8
months in the groups receiving CB or CBM. The HR for disease
progression was 0.56 (95% CI, 0.37–0.86; P¼ 0.007; Figure 2).
Among patients with RAS WT tumour, the median PFS was 6.0
months in the group receiving C and 8.6 months in the groups
receiving CB or CBM (HR 0.69; 95% CI, 0.49–0.97; P¼ 0.03;
Figure 2). The additional benefit of bevacizumab on PFS was not
significantly greater among the patients with RAS WT tumours
than among those with RAS MT tumours (P¼ 0.54 for the
interaction between RAS status and the assigned treatment).
For patients with PIK3CA MT tumours, the median PFS was 9.9
months in the group receiving C and 8.5 months in the groups
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Figure 1. CONSORT diagram MAX AGITG TRIAL: RAS analysis.
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Table 1. Patient demographic and clinical characteristics
RAS PI3KCA
Characteristics
% Of all patients
(N¼471)
% WT
(n¼171)
% MT
(n¼109) P-valuea
% WT
(n¼246)
% MT
(n¼30) P-valuea
Age, years
Median 67 68 68 0.81 68 65 0.29
Range 32–86 36–85 37–85 32–85 41–85
Male sex 63 64 58 0.31 62 63 1.00
ECOG performance status
0 56 60 59 0.46 58 57 0.95
1 38 33 38 36 40
2 6 7 4 6 3
Capecitabine dosage, mgm2 per day
2000 67 63 70 0.30 67 63 0.69
Disease-free interval 412 months 27 30 28 0.79 32 17 0.14
Prior adjuvant chemotherapy 22 23 21 0.77 24 17 0.49
Prior radiotherapy 13 11 8 0.54 10 10 1.00
Primary site of cancer
Caecum 10 8 14 0.11 9 13 0.51
Ascending colon 10 11 14 0.58 13 7 0.55
Transverse colon 6 7 6 0.80 7 3 0.70
Descending colon 3 4 4 1.00 3 3 1.00
Sigmoid colon 30 30 29 1.00 28 47 0.04
Rectosigmoid colon 11 15 9 0.20 13 13 1.00
Rectum 23 21 22 0.88 22 10 0.16
Primary tumour resected 79 93 88 0.20 91 100 0.14
Any metastases resected 10 9 7 0.66 7 17 0.09
Extent of disease at baseline
Local disease in colon or rectum 36 27 32 0.42 28 20 0.39
Liver metastases 75 72 76 0.49 72 83 0.20
Lymph node metastases 47 49 45 0.54 46 57 0.34
Lung metastases 39 37 45 0.21 41 47 0.56
Bone metastases 4 4 5 0.76 3 7 0.25
Peritoneal metastases 18 18 15 0.51 19 3 0.04
Other metastases 10 12 12 1.00 12 13 0.77
BRAF mutationb 11 15 1 o0.001 11 7 0.46
Abbreviations: ECOG¼ Eastern Cooperative Oncology Group; MT¼mutated; WT¼wild type.
aP-value is for the comparison between MT and WT within the RAS and PI3KCA cohorts respectively.
bTotal number of patients with BRAF assessment was 313, with only 278 also having RAS testing and only 274 also having PI3KCA testing.
Table 2. Progression-free survival in the total study population and the patients evaluated for RAS mutation
Total study population (N¼471) Patients evaluated for RAS (n¼280) Patients without tissue (n¼191)
Treatment N
Median PFS
(months) HR 95% CI P-value N
Median PFS
(months) HR 95% CI P-value N
Median PFS
(months) HR 95% CI P-value
C 156 5.7 1.00 95 6.1 1.00 61 5.1 1.00
CB 157 8.5 0.62 0.50–0.79 o.0001 99 9.1 0.63 0.47–0.85 0.002 58 7.4 0.59 0.40–0.85 0.005
CBM 158 8.4 0.59 0.47–0.75 o.0001 86 8.4 0.66 0.49–0.90 0.009 72 8.3 0.48 0.34–0.70 o0.001
CB þ CBM 315 8.4 0.61 0.50–0.74 o.0001 185 8.6 0.65 0.50–0.84 0.001 191 8.2 0.53 0.38–0.73 o0.001
Abbreviations:C¼ capecitabine; CB¼ capecitabine and bevacizumab; CBM¼ capecitabine, bevacizumab and mitomycin; CI¼ confidence interval; HR¼ hazard ratio; PFS¼progression-free
survival.
Table 3. Overall survival in the total study population and the patients evaluated for RAS (and PIK3A) mutation
Total study population (N¼471) Patients evaluated for RAS(n¼280)
Treatment N
Median OS
(months) HR 95% CI P-value N
Median OS
(months) HR 95% CI P-value
C 156 18.9 1.00 95 21.4 1.00
CB 157 18.9 0.86 0.66–1.11 0.24 99 20.4 0.90 0.65–1.26 0.55
CBM 158 16.4 1.00 0.78–1.29 0.98 86 17.3 1.02 0.73–1.44 0.90
CB þ CBM 315 17.3 0.93 0.75–1.16 0.51 185 19.4 0.96 0.71–1.28 0.77
Abbreviations: C¼ capecitabine; CB¼ capecitabine _ bevacizumab; CBM¼ capecitabine, bevacizumab and mitomycin; CI¼ confidence interval; HR¼ hazard ratio; OS¼overall survival.
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receiving CB or CBM (HR, 1.48; 95% CI, 0.61–3.58; P¼ 0.38;
Figure 2). Among patients with PIK3CA WT tumours, the median
PFS was 5.9 months in the group receiving C and 8.4 months in the
groups receiving CB or CBM (HR, 0.58; 95% CI, 0.44–0.77;
Po0.001; Figure 2). The additional benefit of bevacizumab on PFS
appears greater among the patients with PIK3CA WT tumours
than among those with PIK3CA MT tumours but does not reach
statistical significance (P¼ 0.06 for the interaction between
PIK3CA status and the assigned treatment).
Overall survival. Among patients with RAS MT tumours, there
was no statistical difference in OS, and the median OS was 22.8
months in the group receiving C and 20.4 months in the groups
receiving CB or CBM (HR, 0.91; 95% CI, 0.58–1.44; P¼ 0.70).
Among patients with RAS WT tumours, the median OS was 20.6
months in the group receiving C and 18.9 months in the groups
receiving CB or CBM (HR, 0.99; 95% CI, 0.67–1.45; P¼ 0.95). The
effect of the addition of bevacizumab on OS was not significantly
greater among the patients with RAS WT tumours than among
those with RAS MT tumours (P¼ 0.73 for the interaction between
RAS status and the assigned treatment).
Among patients with PIK3CA MT tumours, the median OS was
18.9 months in the group receiving C and 19.2 months in the
groups receiving CB or CBM (HR, 1.18; 95% CI, 0.46–3.06;
P¼ 0.73). Among patients with PIK3CA WT tumours, the median
OS was 20.6 months in the group receiving C and 19.8 months in
the groups receiving CB or CBM (HR, 0.89; 95% CI, 0.65–1.22;
P¼ 0.47). The effect of the addition of bevacizumab on OS was not
significantly greater among the patients with PIK3CAWT tumours
than among those with PIK3CA MT tumours (P¼ 0.49 for the
interaction between PIK3CA status and the assigned treatment).
Response to treatment. The response rate based on RAS and
PIK3CA mutation status is summarised in Table 4 and
Supplementary Table 2 online. Patients with RAS WT tumour
appeared to have a borderline greater likelihood of response with
the addition of bevacizumab (P¼ 0.04 for the interaction between
RAS status and the assigned treatment). The effect of the addition
of bevacizumab on response was similar among the patients with
PIK3CA WT tumours compared with those with PIK3CA MT
tumours (P¼ 0.26 for the interaction between PIK3CA status and
the assigned treatment).
Prognostic value of RAS and PIK3CA mutation. There was no
significant difference in PFS between patients with RAS MT
tumours and those with RAS WT tumours. The median PFS was
7.7 months among the patients with RAS MT tumours as
compared with 7.6 months among those with RAS WT tumours
(HR (RAS WT vs MT), 0.92; 95% CI, 0.71–1.17; P¼ 0.49).
Similarly, RAS has no prognostic impact on OS (Figure 3A), with
median OS of 20.4 months for RAS MT tumours compared with
19.7 months for RAS WT tumours (HR (RAS WT vs MT), 0.94;
95% CI, 0.71–1.24; P¼ 0.65). Multivariate analysis did not change
these results significantly (results not shown).
There was also no significant difference in PFS and OS between
patients with PIK3CA MT tumours and those with PIK3CA WT
tumours. The median PFS was 8.8 months among the patients with
PIK3CA MT tumours as compared with 7.5 months among those
with PIK3CA WT tumours (HR (PIK3CA WT vs MT), 0.90; 95%
CI, 0.60–1.35; P¼ 0.61). The median OS was 19.2 months among
patients with PIK3CA MT tumours as compared with 20.4 months
among those with PIK3CA WT tumours (HR (PIK3CA WT vs
MT), 1.06; 95% CI, 0.68–1.66; P¼ 0.77; Figure 3B). Multivariate
analysis did not change these results significantly (results not
shown).
Sensitivity analysis. As there was higher rate of primary resection
and lower rate of residual local disease in the patients who were
evaluated for RAS and PIK3CA mutations as compared with those
without tissue, we perform sensitivity analysis by adjusting for
these baseline factors. With adjustment, RAS remained nonpre-
dictive of benefit for bevacizumab (PFS: P¼ 0.62, OS: P¼ 0.95 for
the interaction between RAS status and the assigned treatment).
PIK3CA also remained nonpredictive of benefit for bevacizumab
(PFS: P¼ 0.06, OS: P¼ 0.47 for the interaction between PIK3CA
status and the assigned treatment).
DISCUSSION
We have previously shown that KRAS exon 2 mutation status is
not predictive of bevacizumab effect despite the proposed cross-
talk between the EGFR and VEGF signalling pathways (Ellis,
2004). Given the recently reported data on the frequency and
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Figure 2. Hazard ratios for progression-free survival according to RAS
and PIK3CA. Forest plot to demonstrate hazard ratios for progression-
free survival in subgroup analyses by RAS and PIK3CA status.
Table 4. Response rate by RAS and PI3KCA status
RAS PI3KCA
Treatment WT (%) MT (%) P-valuea WT (%) MT (%) P-valuea
C 28.6 48.7 0.04b 34.2 60.0 0.26
CB 39.3 26.3 37.2 36.4
CBM 46.3 50.0 46.9 55.6
Abbreviations: C¼ capecitabine; CB¼ capecitabine and bevacizumab; CBM¼ capecitabine,
bevacizumab and mitomycin; MT¼mutated; WT¼wild type.
aP-value for interaction between biomarker status and the assigned treatment (C vs CB
or CBM).
bResults could not be confirmed when additional analysis comparing C with CBM only was
undertaken (P¼ 0.25 for the interaction between RAS status and the assigned treatment).
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relevance of additional RASmutations on prediction for anti-EGFR
therapy, we aimed to assess the mutation rate in the MAX trial as
an extension of our prior analysis (Price et al, 2011). In our
population we now show that 1 in 10 patients (10%) considered
KRAS WT have an additional RAS mutation. Despite these
additional mutations, there was still no predictive effect on the
outcome of bevacizumab, and RAS mutation status remained
nonprognostic.
The MAX trial reported improved PFS with the addition of
bevacizumab to capecitabine when compared with capecitabine
alone. The potential impact of KRAS mutation status on outcomes
with bevacizumab had been questioned and this led to a number of
investigators to undertake retrospective analysis of bevacizumab
trials, our group being one of them. The finding that up to 23% of
KRAS exon 2 WT patients may have additional RAS mutation led
us to re-analyse our data set with extended RAS results. Of the
patients, 59% had available tissue for RAS assessment. Outcomes
for PFS and OS were consistent between the intention-to-treat
(ITT) and tissue population (Tables 2 and 3). Consistent with the
primary analysis, PFS was improved by a similar magnitude and
there was no apparent impact of the extended RAS status (HR, 0.56
RAS MT and 0.69 RAS WT, P for interaction between RAS status
and assigned treatment¼ 0.54). These data for extended RAS are
consistent with the retrospective analyses of the MAX and the
pivotal Hurwitz study (IFL±bevacizumab) for exon 2 KRAS MT
(Ince et al, 2005; Hurwitz et al, 2009). In contrast to the study of
Hurwitz et al (2009) where only 31.3% of patient’s tissue was
assessable, our data set has 60% of the ITT population available for
analysis and thus we are able to confirm that changes in RAS MT
rates has not altered our prior conclusions.
We detected extended RAS mutations in 39% of the patient
group with available tissue. Importantly, 10% of patients previously
labelled KRAS (exon 2) WT harboured an additional RAS
mutation. The proportion of exon 2 WT patients with an
additional RAS mutation is less than reported in the published
series with panitumumab and cetuximab (PRIME 17%, FIRE-3
16% and PEAK 23%) (Douillard et al, 2013; Heinemann et al,
2014; Schwartzberg et al, 2014). Subsequently, investigators from
the CRYSTAL and OPUS studies have reported in abstract form
additional RASMT rates of 15% and 26%, respectively (Bokemeyer
et al, 2014; Ciardiello et al, 2014). The difference may be explained
partly as the MAX trial represented an older population considered
suitable for bevacizumab and single-agent fluorouracil. Although
there is no definite evidence that KRAS exon 2 MT rate may differ
with age, additional mutations may vary and Russo et al (2014)
recently reported different rates of NRAS MT based on age. Thus,
subtle differences in these patient populations and patient
characteristics may explain the lower rate of additional RAS
mutations seen here. It is also likely that the method chosen to
detect mutations will have differing sensitivity and recommended
cutoff percentages, resulting in variation in reported rates of
mutation (Whitehall et al, 2009; Pinto et al, 2011). Here, for
example, we used pyrosequencing that differs with the method
used by the PRIME and PEAK investigators who chose
bidirectional sanger sequencing and WAVE-based surveyor kits.
The investigators from the CRYSTAL and OPUS studies used the
BEAMing technique. Although this is one of the most sensitive
techniques reported, a 5% sensitivity cutoff was chosen for these
analyses to be consistent with other literature. Variation between
the technique chosen is further highlighted by the NRAS exon 4
results that appear only detectable when using BEAMing. Only
the FIRE-3 investigators used pyrosequencing and their extended
RAS MT rate was one of the lowest reported. Ultimately,
differences in patient populations within trials and the sensitivity
of the methods used will lead to a range of RAS mutations rates.
The exact frequency will become clearer as additional studies are
analysed and this will help define the optimal technique and
sensitivity cutoff for clinical practice.
The PI3K signalling is considered to regulate tumour growth
and angiogenesis by activating AKT and other targets, as well as
inducing VEGF and HIF-1 expression (Jiang and Liu, 2009; Zhang
et al, 2012). Furthermore, Soler et al (2013) have reported in a
mouse model that inactivation of PIK3CA leads to increased
vascular density, reduced vessel size and altered pericyte coverage,
and thus PIK3CA has a role in regulation of vessel formation. As
there is evidence for a potential interaction of PIK3CA and
angiogenesis, and importantly as a biomarker for guiding
antiangiogenic therapy remains elusive, we decided to explore
whether there was any signal for an association between PIK3CA
mutation status and outcome. In the MAX patients PIK3CA
mutation was seen in 11.1% of patients (7.5% exon 9 and 3.6%
exon 20). We chose to combine PIK3CA MT (exons 9 and 20) for
this analysis. In contrast to prior studies assessing MT status and
activity of anti-EGFR therapy (De Roock et al, 2010, 2011) where
only exon 20 is relevant for predicting outcome, there is no
suggestion of a similar relationship with a specific mutation when
considering a potential interaction with the VEGF pathway (Zhang
et al, 2012). Furthermore, the small numbers of each PIK3CA exon
MT would make results difficult to interpret. Despite theoretical
relationships between PIK3CA and angiogenesis and VEGF
activation, we found no predictive effect. The borderline trend to
a reduced effect of bevacizumab in the PIK3CA MT patients is
likely because of small numbers, although ultimately larger data
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Figure 3. Kaplan–Meier curves for overall survival according to RAS and
PIK3CA status. A comparison of the overall survival of all patients
according to their (A) RAS and (B) PIK3A status
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sets or prospective analysis will be required to asses whether this
outcome is real. Furthermore, differences in response rate are also
likely to be a random phenomenon based on the small sample
size. That said, and although not directly comparable, patients
with PIK3CA MT treated with the combination of bevacizumab,
temsirolimus and liposomal doxorubicin had the opposite
outcome with improved response rates when compared with
those with WT PIK3CA, potentially supporting some interaction
of VEGF pathway (Moroney et al, 2012), and further analysis of
larger data sets may therefore be appropriate. Finally, in keeping
with a number of publications, we found no indication that
PIK3CA MT was prognostic. When considering whether
investigators should assess PIK3CA based on individual exon or
combined, evidence from Liao et al (2012) recently found that
neither exon 9 nor 20 was prognostic when assessed indepen-
dently, supporting a combined analysis particularly given the
small numbers.
It is important to comment on the potential limitations of a
subset analysis. This study is restricted to 59.4% of the tissue that
was available for mutation analysis and hence not necessarily
generalisable to the broader population. However, the results of
our study still demonstrate good internal validity. There is no
strong evidence to support that either RAS or PIK3CA is a
predictive factor for bevacizumab benefit. The available tissue was
obtained at the time of study enrolment and not post hoc after the
primary trial result became available. Although there is an in
balance between the tissue population and ITT population in
terms of primary in situ, this is balanced in each analysis. Thus,
although this may be prognostic, the outcomes for bevacizumab
benefit are unaltered. Although there might be differences in
patients’ baseline characteristics between those with and without
tissue (Supplementary Table 1), such differences might exist for
patients not enrolled in the MAX trial. Furthermore, sensitivity
analysis performed to adjust for these different baseline
characteristics does not change the overall conclusion of this
study.
In conclusion, our analysis of extended RAS and PIK3CA
mutation status from the MAX trial tissue population did not find
any therapeutic relevance of mutation status of either RAS or
PIK3CA when bevacizumab is given in combination with
capecitabine chemotherapy. The RAS and PIK3CA status was not
prognostic for metastatic CRC for PFS or OS. Finally, we confirm
that a clinically relevant proportion of patients (10%) considered
KRAS exon 2 WT have an additional mutation in the RAS
pathway.
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